Health Trials

Advanced Malignant Solid Tumours

3

Review clinical trials related to Advanced Malignant Solid Tumours. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour. Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage.

Participants needed: 374
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Junshi Bioscience Co., Ltd.Updated: Jun 19, 2025Locations: 1
Eligibility criteria

Subjects of either sex who are 18 to 75 years of age (inclusive of 18 and 75 yea... [+4]

Presence of active central nervous system metastasis. If previous radiotherapy o... [+6]

Read more
Status: Recruiting

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Participants needed: 441
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sinocelltech Ltd.Updated: Jan 16, 2025Locations: 1
Eligibility criteria

Voluntarily sign the informed consent form (ICF); [+6]

Participants with brainstem, meningeal, spinal metastases, orcompression; active... [+13]

Read more
Status: Not yet recruiting

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Participants needed: 515
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Sinocelltech Ltd.Updated: Mar 15, 2024
Eligibility criteria

Voluntarily sign the informed consent form (ICF); [+6]

Participants with brainstem, meningeal, spinal metastases, or compression; activ... [+11]

Read more